First‐in‐Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15‐Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis

Utreloxastat (PTC857) is a 15‐lipoxygenase inhibitor being developed to treat amyotrophic lateral sclerosis. This first‐in‐human study investigated the safety and pharmacokinetics of utreloxastat in healthy volunteers (N = 82) in a double‐blind, placebo‐controlled trial. The effects of a single asce...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lan, Giannousis, Peter, Thoolen, Martin, Kaushik, Diksha, Latham, Joey, Tansy, Aaron, Ma, Jiyuan, Johnston, Mayzie, Dali, Mandar, Golden, Lee, Klein, Matthew, Kong, Ronald, Trimmer, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107758/
https://www.ncbi.nlm.nih.gov/pubmed/36516010
http://dx.doi.org/10.1002/cpdd.1203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107758/
https://www.ncbi.nlm.nih.gov/pubmed/36516010
http://dx.doi.org/10.1002/cpdd.1203

Ejemplares similares